SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 7)
NEOTHERAPEUTICS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON
--------------------------------------------------------------------------------
(Title of Class of Securities)
640656104
--------------------------------------------------------------------------------
(CUSIP Number)
12/31/01
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[X] Rule 13d-1(b)
[_] Rule 13d-(c)
[_] Rule 13d-1(d)
----------
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(SC13G-07/98)
CUSIP No. 640656104 13G Page of Pages
________________________________________________________________________________
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
INGALLS & SNYDER, LLC
13-5156620
_________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
NEW YORK STATE
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 309,922 (Assuming exercise of 10,900 warrants.)
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY -0-
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 309,922 (Assuming exercise of 10,900 warrants.)
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH 2,022,079 (Assuming exercise of 57,200 warrants.)
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,332,001 (Assuming exercise of 68,100 warrants.)
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.1% (Assuming exercise of 68,100 warrants.)
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
BD
________________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP No. 640656104 13G Page of Pages
________________________________________________________________________________
Item 1(a). Name of Issuer:
Neotherapeutics, Inc.
________________________________________________________________________________
Item 1(b). Address of Issuer's Principal Executive Offices:
157 Technology Drive
Irvine, CA 92618
________________________________________________________________________________
Item 2(a). Name of Person Filing:
Ingalls & Snyder LLC
________________________________________________________________________________
Item 2(b). Address of Principal Business Office, or if None, Residence:
61 Broadway
New York, NY 10006
________________________________________________________________________________
Item 2(c). Citizenship:
New York State LLC
________________________________________________________________________________
Item 2(d). Title of Class of Securities:
COMMON
________________________________________________________________________________
Item 2(e). CUSIP Number:
640656104
________________________________________________________________________________
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b)
or (c), Check Whether the Person Filing is a:
(a) [X] Broker or dealer registered under Section 15 of the Exchange Act.
(b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange
Act.
(d) [_] Investment company registered under Section 8 of the Investment
Company Act.
(e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [_] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act;
(i) [_] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act;
(j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Rule 13d-1(c), check this box. [_]
CUSIP No. 640656104 13G Page of Pages
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
2,332,001 (Assuming exercise of 68,100 warrants.)
(b) Percent of class:
10.1% (Assuming exercise of 68,100 warrants.)
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
309,922 (Assuming exercise of 10,900 warrants.)
(ii) Shared power to vote or to direct the vote: -0-
(iii) Sole power to dispose or to direct the disposition of:
309,922 (Assuming exercise of 10,900 warrants.)
(iv) Shared power to dispose or to direct the disposition of:
2,022,079 (Assuming exercise of 57,200 warrants.)
________________________________________________________________________________
Item 5. Ownership of Five Percent or Less of a Class.
________________________________________________________________________________
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
________________________________________________________________________________
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
________________________________________________________________________________
Item 8. Identification and Classification of Members of the Group.
________________________________________________________________________________
Item 9. Notice of Dissolution of Group.
________________________________________________________________________________
Item 10. Certifications.
(a) The following certification shall be included if the statement is
filed pursuant to Rule 13d-1(b):
"By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are held in
the ordinary course of business and were not acquired and not held for
the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are
not held in connection with or as a participant in any transaction
having such purpose or effect."
(b) The following certification shall be included if the statement is
filed pursuant to Rule 13d-1(c):
"By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having such purpose or effect."
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
02/13/02
----------------------------------------
(Date)
Ingalls & Snyder LLC by
/s/ Edward H. Oberst
----------------------------------------
(Signature)
Edward H. Oberst
Managing Director
----------------------------------------
(Name/Title)
Note. Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties for whom copies are to be sent.
Attention. Intentional misstatements or omissions of fact constitute federal
criminal violations (see 18 U.S.C. 1001).